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Summary Uromodulin (UMOD) malfunction has
been found in a range of autosomal dominant tubu-
lointerstitial nephropathies associated with hyperuri-
caemia, gouty arthritis, medullary cysts and renal
failure—labelled as familial juvenile hyperuricaemic
nephropathy, medullary cystic disease type 2 and
glomerulocystic kidney disease. To gain knowledge of
the spectrum of UMOD changes in various genetic
diseases with renal involvement we examined urinary
UMOD excretion and found significant quantitative
and qualitative changes in 15 male patients at various
clinical stages of Fabry disease. In untreated patients,
the changes ranged from normal to a marked decrease,
or even absence of urinary UMOD. This was accom-
panied frequently by the presence of aberrantly
processed UMOD lacking the C-terminal part follow-
ing the K432 residue. The abnormal patterns normal-
ized in all patients on enzyme replacement therapy
and in some patients on substrate reduction therapy.
Immunohistochemical analysis of the affected kidney
revealed abnormal UMOD localization in the thick
ascending limb of Henle_s loop and the distal convo-
luted tubule, with UMOD expression inversely propor-
tional to the degree of storage. Our observations
warrant evaluation of tubular functions in Fabry
disease and suggest UMOD as a potential biochemical
marker of therapeutic response of the kidney to
therapy. Extended comparative studies of UMOD
expression in kidney specimens obtained during indi-
vidual types of therapies are therefore of great interest.
Abbreviations
DCT distal convoluted tubule
ERT enzyme replacement therapy
Gb3 globotriaosylceramide
GLA !-galactosidase A
MALDI-TOF matrix assisted lased desorption/
ionization-time of flight
SRT substrate reduction therapy
TALH thick ascending limb of Henle_s loop
UAKD uromodulin-associated kidney disease
UMOD uromodulin
Introduction
Uromodulin (UMOD; OMIM 191845) or Tamm–Horsfall
protein (THP) is a protein selectively expressed in the
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thick ascending limb of Henle_s loop (TALH), the
macula densa segment and the distal convoluted
tubule (DCT) (Hoyer and Seiler 1979; Peach et al
1988; Schenk et al 1971; Sikri et al 1981). Normally the
synthesized protein is glycosylated, glypiated, secreted
and glycosylphosphatidylinositol-anchored in the
apical membrane of the polarized renal tubular
epithelial cells (Kreft et al 2002; Rindler et al 1990;
Serafini-Cessi et al 1993), from where it is continuously
released by a specific but not yet identified prote-
ase (Cavallone et al 2001; Fukuoka and Kobayashi
2001). UMOD is excreted in the urine at the rate of
50–100 mg/day, which makes it one of the most
abundant urinary proteins (Kumar and Muchmore
1990). UMOD precipitates in the urine and is the
main constituent of urinary casts (Cohen 1981; Fairley
et al 1983; Wenk et al 1981).
Mutations in the uromodulin gene (HGNC UMOD)
were found in a subset of patients suffering from a
range of autosomal dominant tubulointerstitial ne-
phropathies associated with hyperuricaemia, gouty
arthritis, medullary cysts and renal failure—labelled
as familial juvenile hyperuricaemic nephropathy (FJHN,
OMIM 162000), medullary cystic disease type 2 (MCKD2,
OMIM 603860) (Hart et al 2002) and glomerulocystic
kidney disease (GCKD, OMIM 609886) (Rampoldi
et al 2003). In these patients UMOD mutations led
to intracellular UMOD accumulation, absence of
the protein on the plasma membrane and decreased
urinary excretion (Bernascone et al 2006; Bleyer
et al 2004; Dahan et al 2003; Hodanova et al 2005;
Rampoldi et al 2003; Vylet_al et al 2006). Changes in
UMOD expression, cellular localization and urinary
excretion were found also in FJHN/MCKD patients
with no UMOD mutation and this led to introduction
of the term Furomodulin-associated kidney diseases_
(UAKD) (Hart et al 2002; Hodanova et al 2005;
Vylet_al et al 2006).
As it is unclear as to what extent the changes in
UMOD expression, cellular localization and urinary
excretion are specific to FJHN/MCKD/UAKD, we are
examining these parameters in other genetic diseases
with severely compromised renal functions.
Fabry disease (OMIM 301500) is an X-linked,
gonosomal recessive disorder caused by deficiency of
a-galactosidase A (GLA; EC 3.2.1.22.). The enzyme
defect leads to massive accumulation and storage of
non-degraded substrate globotriaosylceramide (Gb3)
in lysosomes of various cell types. Hemizygous male
patients manifest a wide range of symptoms, including
characteristic skin lesions, chronic progressive painful
small-fibre neuropathy, corneal opacities, renal failure,
heart disease and stroke due to systemic vasculopathy.
If untreated, the disease is lethal, renal failure being
the usual cause of death (Desnick et al 1989; Masson
et al 2004).
The Fabry storage nephropathy has attracted bio-
medical interest mainly owing to deterioration of
glomerular function, starting with increased protein
permeability, followed by progressive hyalinization
and loss of the filtration capacity. This process as
such has been studied intensively at clinical and
pathological levels (Burkholder et al 1980; Glass et al
2004; McNary and Lowenstein 1965; Morel-Maroger
et al 1966; Pabico et al 1973) among others with
the intention of defining Fthe point of no return_ for
enzyme replacement therapy (ERT) (Breunig and
Wanner 2003; De Schoenmakere et al 2003; del Toro
et al 2004). Renal tubular dysfunction in Fabry disease
was described earlier by Pabico and colleagues (Pabico
et al 1973) but attracted little attention. However,
tubular dysfunction has been described as being
prominent during the early clinical course (Parchoux
et al 1978; Wornell et al 2006).
In this study of 15 male Fabry disease patients in
various clinical stages of the disease, we examined
UMOD urinary excretion and protein proteolytic
processing and found significant quantitative and
qualitative abnormalities. Interestingly, these changes
normalized in every single patient treated by ERT
(Fabrazyme or Replagal) but not as successfully in the
patients on substrate reduction therapy (SRT) using
the ceramide glucosyltransferase inhibitor Zavesca.
To explain the observed abnormalities we studied
UMOD cellular localization in different parts of the
nephron and collecting duct in kidney tissue from
three untreated patients. These studies revealed ab-
normal UMOD localization in TALH and collecting
tubules, with UMOD expression in TALH epithelia
being inversely proportional to the degree of storage.
In contrast to previous studies, which have largely
looked at functional changes, our study shows for the
first time a biochemically defined alteration of tubular
cell biology reflecting the process of storage in defined
parts of the nephron. Although the mechanisms by
which the enzyme defect and/or storage process lead to
abnormal UMOD expression, processing and urinary
excretion remain unknown. Our observations warrant
further evaluation of tubular functions in Fabry
disease patients and suggest UMOD as a potential
biochemical marker of response of the kidney to
therapy.
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Materials and methods
Patients
For the analyses, urine samples were collected from 15
male patients with Fabry disease with a range of ages,
severity of symptoms and types of treatment. The
diagnosis of Fabry disease in the selected patients was
made following the finding of reduced GLA activity in
leukocytes and the presence of a pathogenic mutation
in the GLA gene (HGNC GLA). Basic clinical,
biochemical and molecular data as well as the treat-
ment regimens for all 15 patients are summarized in
Table 1. All the patients were from the Czech
Republic and were diagnosed and studied in our
Institute (Dobrovolny et al 2005).
SDS-PAGE and western blot
Urine samples stored at j80-C were thawed and
15 ml of sample was denatured using standard SDS-
PAGE loading buffer. Proteins were separated on
10% SDS–polyacrylamide gel and UMOD was
detected using western blot analysis as described
previously (Hodanova et al 2005).
Deglycosylation experiments
Deglycosylation experiments were performed on 15 ml
of total urine using the GlycoPro enzymatic deglyco-
sylation kit (ProZyme Inc., San Leandro, CA, USA)
according to the manufacturer_s instructions. Deglyco-
sylated protein products were directly analysed on
10% SDS–polyacrylamide gel and UMOD was
detected by western blot as described above.
Mass spectrometry
To characterize UMOD variants, total protein from
500 ml of each patient_s urine was recovered on Micro-
con YM-50 columns (Milipore, Bedford, MA, USA)
and separated on 10% SDS–polyacrylamide gel. Coo-
massie blue R 250 stained protein bands were extracted
from the gel and digested with trypsin (Promega,
Madison, WI, USA, 5 ng/ml). The resulting peptides
were extracted and subjected to mass-spectrometric
analysis.
Mass spectra were measured using the following. (a)
A matrix-assisted laser desorption/ionization reflec-
tron time-of-flight MALDI-TOF mass spectrometer
BIFLEX II (Bruker-Franzen, Bremen, Germany)
equipped with a nitrogen laser (337 nm) and gridless
delayed extraction ion source. Spectra were calibrated
externally using the monoisotopic [M+H]+ ion of
peptide standard somatostatin (Sigma-Aldrich, Prague,
Czech Republic). A saturated solution of a-cyano-4-
hydroxycinnamic acid in 50% CAN–0.2% TFA was
used as a MALDI matrix. (b) A LCQDECA ion trap
mass spectrometer (ThermoQuest, San Jose, CA,
USA) equipped with a nanoelectrospray ion source
(ESI LC-MS/MS). Magic-C18 column, 0.2150 mm,
200 A˚, 5 mm (Michrom Bioresources, Auburn, CA,
Table 1 Clinical, biochemical and molecular information on patients
Patient DOB GLA mutation GLA activitya Mainz score Renal index Treatmentb
P1 1945 c.801ins36 2.4 34 0 Z(12), F(12)
P2 1949 delEx2 2.6 56 18 Z(12), F(45)
P3 1952 R301X 2.9 54 18 Z(12), F
P4 1957 L294X 1.0 54 18 Z, T, F(5)
P5 1960 c.801ins36 1.7 41 4 Z, F(14)
P6 1968 c.674del59 0.7 41 18 R(2)
P7 1972 N215S 7.2 – 0 N
P8 1978 D155H 1.7 41 18 Z, F
P9 1979 N215S 5.2 5 0 N
P10 1985 G360S 1.9 – 0 N
P11 1956 Q280K 1.2 35 4 Z(12), F(45)
P12 1978 R342Q 3.4 32 8 R(3)
P13 1972 R342Q 0.3 41 4 R(3)
P14 1966 R342Q 1.8 28 0 Z(12)
P15 1948 R301X 1.9 44 4 Z(12), F(13)
a GLA activity in leukocytes measured at 37-C; average of 100 controls 53.8T11,5 and range 32–89 nmol/mg per hour.
b Z, Zavesca; F, Fabrazyme; R, Replagal; N, none; T, transplantation; duration of the treatment is given in months in parentheses.
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USA) and MeCN–acetic acid gradient was used for
peptide separation. Positive-ion full scan and CID
mass spectra over m/z range 350–1600 were acquired
and interpreted by SEQUEST software against the
human NCBI database.
Immunohistochemistry studies
Archived formalin-fixed paraffin-embedded kidney
samples originated from two autopsied adult males
and one female with Fabry disease, who died at 47, 44
and 63 years respectively. The storage was detected in
fixed frozen section, using the periodic acid–Schiff
(PAS) method (checked by lipid extraction) and by
birefringence. In paraffin sections, it was indicated by
the typical foamy appearance of the storage cells.
Immunodetection of UMOD and of the apical cell
membrane marker MUC1 was done in paraffin sec-
tions as previously described (Vylet_al et al 2006). For
designation of individual parts of the kidney tubular
system the nomenclatures of Clapp and Croker was
used (Clapp and Croker 1997), i.e. nephron (consisting
of proximal tubule, Henle loop and distal convoluted
tubule) and the collecting tubule.
Results
Analysis of urinary UMOD
For an overview on the nature and range of eventual
changes in urinary UMOD excretion we analysed
urine samples from 15 Fabry patients with a range of
age, severity of symptoms and treatment regimens
(Table 1).
Initially, we analysed UMOD excretion patterns in
urine samples collected before any treatment was
started (Fig. 1). The analysis showed that in some of
the patients UMOD excretion was strongly decreased
(P3, P8) or reduced (P5), along with abnormal forms
of anti-UMOD immunoreactive protein (P1, P2, P3,
P5, P6, P8, P11, P15). In other patients, UMOD
excretion seemed to be normal (P4, P7, P9, P10, P12,
P13, P14). As indicated in Table 1, P4 was tested after
kidney transplantation and patients P7, P9 and P10
showed a mild clinical phenotype.
To identify the nature of the anti-UMOD immuno-
reactive protein found in urines of some Fabry disease
patients, we first deglycosylated urine from patient P1
with N-glycanase (PGNase F) and subjected the
resulting UMOD profile to western blot analysis
(Fig. 2a). The analysis suggested that the abnormal
anti-UMOD immunoreactive protein did not represent
a different UMOD glycoform but rather a UMOD
protein differing in its peptide moiety. We therefore
recovered total protein from the urine sample of P1,
separated the proteins on SDS-polyacrylamide gel,
detected corresponding protein bands by Coomassie
blue staining (Fig. 2b), excised them and analysed
them by mass spectrometry (Fig. 2c). The analysis
showed that the abnormal protein with the lower
molecular mass was UMOD lacking a C-terminal part.
With K432 being the last amino acid positively
identified, the cleavage site leading to this abnormal
proteolytic processing is most likely to be located
between amino acid residues K432 and R449 (Fig. 2d).
The patients chosen for this study were enrolled in
three different treatment protocols using either the
synthetic ceramide glucosyltransferase inhibitor
Zavesca (miglustat; Actelion Pharmaceuticals Ltd,
Allschwil, Switzerland) or two available recombinant
GLA preparations, Fabrazyme (Genzyme, Cambridge,
MA, USA) and Replagal (Shire Human Genetic
Therapies AB, Danderyd, Sweden). To investigate
eventual effects of the treatment protocols on abnor-
mal UMOD excretion and processing, we analysed
urine samples collected before and during the individ-
ual trials (Fig. 3). Abnormal processing of UMOD
clearly normalized in all patients receiving ERT with
Fabrazyme (Fig. 3b) and Replagal (Fig. 3c). The effect
of Zavesca treatment was not as striking (Fig. 3a).
UMOD expression in situ and its relation
to the storage process
To explain the observed abnormalities in urinary
UMOD excretion and processing, we studied UMOD
cellular expression and its relation to the storage in
different parts of nephron and collecting duct in
archived kidney tissues from two untreated hemizygotes
and one heterozygous patient whose urine samples were
unfortunately not available for correlation.
Fig. 1 Qualitative analysis (western blot) of urinary UMOD in
patients with Fabry disease before the therapy. U: UMOD
standard isolated from control urine. C: control urine. P1–P15:
patient designation as provided in Table 1
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Fig. 2 Characterization of abnormal UMOD processing. (a)
Qualitative analysis (western blot) of UMOD isolated from
healthy male urine before (Uj) and (U+) after deglycosylation
treatment with N-glycanase. P1j indicates urine from patient P1
before and P1+ after deglycosylation treatment with N-glyca-
nase. (b) Qualitative analysis (Coomassie blue-stained SDS-
PAGE gel) of total protein extract obtained from 500 ml of urine
from patient P1 on Amicon YM-50. U: UMOD standard isolated
from control urine. (c) Peptide mass fingerprinting of UMOD
standard (control) and isolated protein of interest confirms that
Fshort form_ is UMOD protein lacking the N-terminal part
following 432K residue. M16 indicates oxidized methionine. C57
indicates cysteine iodoacetamide. (d) Sequence alignment of the
control urinary UMOD (upper sequence) and the patient Fshort
form_ (lower sequence) shows with grey highlight peptides
detected by peptide mass fingerprinting and in bold type
peptides that were confirmed by peptide microsequencing.
Theoretical N-glycosylation sites of UMOD are underlined
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UMOD in situ expression in control kidney samples
was restricted to the epithelial cells of the TALH and
the DCT. In the latter, the expression was lower and
variable. UMOD was maximally expressed in the
apical pole with less intracellular positivity. Exception-
ally there was also staining at the basolateral pole.
Rarely there was slight positivity in some cells in
collecting tubules.
Distribution of the storage in Fabry disease kidneys. In
the cortex, storage was absent in both the proximal
and the distal tubules. It was present only in glomeruli
and in vessels (endothelia and smooth-muscle cells).
The tubular storage dominated in the medullary parts
of the nephron (both descending and ascending limbs
of the loop of Henle) and in the system of collecting
tubules, decreasing from the outer medulla to the
papilla. Corresponding tubular segments (parts) dif-
fered considerably in the degree of storage. In the
collecting tubules, the storage was more pronounced in
the intercalated cells. There were also signs of tubular
regeneration (binucleate cells, cells with flat cyto-
plasm) and degeneration (cell shrinkage and nuclear
pycnosis) and focal fibrosis in the medulla, mainly in
its outer part. The storage pattern in the heterozygous
Fabry kidney was the same as described in both
hemizygotes.
UMOD in situ expression in Fabry disease kidneys.
UMOD signal was present with similar intensity as in
controls in the non-storing TALH and in the DCT.
The number of tubules strongly positive for UMOD in
the cortex was comparable to that in control kidneys
(Fig. 4a, b) but was decreased in the outer medulla
(Fig. 4c, d). In many cross-sections of TALH, there
were strongly UMOD-positive epithelia free of recog-
nizable storage mixed with cells in advanced stage of
storage and decreased or absent UMOD staining
(Fig. 4e). In general, the degree of UMOD expression
was inversely proportional to the degree of lysosomal
storage (Fig. 4f). In cells with lesser degrees of storage,
UMOD apical presentation was preserved but often
combined with staining at the basolateral pole
(Fig. 4g). In some collecting tubules there was UMOD
signal at the cell membrane as well as intracellularly,
suggesting ectopic expression (Fig. 4h). This finding
was more frequent than in controls but was not
entirely bound to advanced lysosomal storage. Several
UMOD-positive luminal casts were also observed.
UMOD staining in the heterozygous Fabry kidney
did not differ from that in the samples from the
hemizygous patients.
In parallel the marker of the apical membrane,
MUC1, was present throughout the whole nephron
Fig. 3 Qualitative analysis (western blot) of urinary UMOD in
patients with Fabry disease on various therapy protocols.
(a) Zavesca protocol. Urine samples were collected (A) before
treatment, (B) at 6 months, (C) at the end of treatment
(12 months) and (D) 1 month after termination of the treatment.
(b) Fabrazyme protocol. Samples taken before and during
the treatment are in plain and bold characters, respectively.
(c) Replagal protocol. Urine samples were collected (A) before
treatment, (B) at 1 month, (E) at 2 months, (C) at 3 months and
(D) 1 month after termination of the treatment. U: uromodulin
standard isolated from control urine, C: control urine, P1–P15:
patient designation as provided in Table 1. The low molecular
weight bands seen at the bottom of images most probably
represent albumin, reflecting disease-related proteinuria
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Fig. 4 Immunohistochemical analysis of UMOD and MUC1 in
kidney biopsies. Survey of the cortical medullary rays shows
strong and comparable UMOD expression (a) in control and (b)
in Fabry disease kidney where cortical TALH is without
prominent lysosomal storage. Differences in UMOD expression
were present in the outer medulla. (c) In the control the staining
in TALH is uniform whereas (d) in Fabry disease kidney the
absence of UMOD staining is seen in many cross-sectioned
TALH displaying storage. Details of the outer medulla in Fabry
disease kidney show (e) absence of UMOD expression in
individual storage TALH cells (arrows) and (f) UMOD expres-
sion in TALH inversely proportional to the degree of storage. (g)
Storage TALH epithelium with persistent decreased apical
UMOD expression (asterisk). (h) Collecting tubules (arrows)
with distinct apical and basolateral UMOD positivity. MUC1
expression is identical in both (i) control and (j) despite the
storage also in Fabry disease kidney
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with the exception of proximal convoluted tubules, and
in the collecting tubules as in controls. There was no
significant reduction of MUC1 expression due to
storage (Fig. 4i, j).
Discussion
We present here the results of a pilot study investigat-
ing UMOD urinary excretion, processing and expres-
sion in patients with Fabry disease at different clinical
stages of the disease and during treatment with ERT
or SRT. This work has been undertaken with the aim
of extending knowledge of the range of UMOD
changes in various genetic diseases with severe renal
involvement, starting with the model of Fabry disease.
In about half of the untreated hemizygous male
patients as well as in 7 out of 9 heterozygous carriers
(data not shown), we found significant quantitative
and qualitative changes in urinary UMOD excretion,
which indicate a gradual decrease in urinary UMOD
excretion accompanied in some cases by aberrant
proteolytic UMOD processing. Variability in UMOD
excretion seemed in most patients to reflect phenotyp-
ic severity (with the exception of P12 and P13) as it
correlates with the reported Mainz severity score
index. This speculation is further supported by the
finding that UMOD urinary excretion patterns nor-
malized in all patients enrolled in ERT and, to a lesser
extent, in patients on SRT. Reversibility of abnormal
UMOD excretion profile after ERT and SRT repre-
sents a key observation as it links the changes of
UMOD biology to the storage process in TALH and
the DCT.
Existing studies addressing the nephron storage
distribution in Fabry disease differ surprisingly with
regard to definition of the individual affected seg-
ments. Storage in the proximal part has been reported
only rarely (Alroy et al 2002; Farge et al 1985; McNary
and Lowenstein 1965; Wornell et al 2006). Storage
in collecting tubules was found to be present in only
two reports (Alroy et al 2002; Burkholder et al 1980),
while others described storage in the distal tubules
(Burkholder et al 1980; Dempsey et al 1965; Faraggiana
et al 1981; Farge et al 1985; Gubler et al 1978; McNary
and Lowenstein 1965; Pabico et al 1973; Tondeur and
Resibois 1969; Wornell et al 2006). The distal tubule
and the Henle loop are thus considered to be affected
most prominently in Fabry disease (Okuda 2000).
The storage pattern in heterozygotes did not differ
substantially from that in hemizygous male patients
(Farge et al 1985; Gubler et al 1978).
We observed storage in the loop of Henle and in the
collecting ducts with notable degrees of variability
between individual tubules. In particular, storage in
the TALH had a mosaic character. Similar variability
in storage has been described before (Gubler et al
1978). As in previous studies on UMOD expression in
control kidney, we observed prominent expression of
UMOD in the TALH and less so in the DCT in
normal kidneys (Hoyer and Seiler 1979; Peach et al
1988; Schenk et al 1971; Sikri et al 1981). Thus, both
processes, lysosomal storage and UMOD expression,
meet in the TALH.
Normal, fully processed UMOD detected in the
patient urine samples is most probably produced by
cells not affected by storage process and showing
UMOD staining like that in controls. Decrease in
UMOD excretion might be attributed to its attenuated
expression as shown by the UMOD staining pattern,
which is inversely proportional to the degree of storage
in patient kidney. Attenuated UMOD expression,
however, cannot be attributed to generally compro-
mised proteosynthesis because another marker of
apical membrane, MUC1, showed normal expression
pattern in unaffected as well as storing cells. Attenu-
ated UMOD expression is thus probably linked
directly to the lysosomal storage process. Similar
decrease in UMOD transcription and expression was
found recently in mice with renal-specific inactivation
of HNF1b (Gresh et al 2004), Brn1j/j mice (Nakai
et al 2003), an ischaemia-reperfusion model of ARF in
rat (Yoshida et al 2002), in some patients with UAKD
(Hodanova et al 2005; Vylet_al et al 2006), and in
kidney damage (Chakraborty et al 2004).
The other interesting observation of our study
represents aberrant proteolytic processing of UMOD.
Our results do not define the site and mechanism of
this process. It may be intracellular as a result of
storage-related proteosome and/or specific protease
activation. It may also occur on the cell membrane by
a process of abnormal ectodomain shedding. This
process may be activated by glomerulopathy-related
changes in tubular fluid composition (proteinuria,
osmolarity, pH), which may alter the tertiary structure
of UMOD and make it susceptible to aberrant cleavage
either by UMOD-specific or other proteases present
in urine. This latter explanation seems more likely as
distinct UMOD staining may be seen on the apical
membrane of storing as well as non-storing epithelial
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cells (Fig. 4). The alternative processing can also
reflect alternative proteolytic cleavage in desquamated
tubular storage epithelia responsible for the massive
urinary lipid excretion.
In conclusion, storage processes in Fabry disease
trigger mechanisms that lead to reduced expression,
alternative proteolytic processing and decreased uri-
nary excretion of UMOD. Lack of UMOD function(s)
has been shown to be associated with impairment of
tubular function, particularly of the urine-concentrat-
ing process, accounting for water depletion in UAKD
(Bleyer et al 2003; Scolari et al 2004; Vylet_al et al
2006). It is therefore reasonable to speculate that the
observed changes in UMOD expression may contrib-
ute to altered tubular functions in Fabry disease as
well. Association of UMOD changes with the degree
of the storage process and its reversibility by ERT and
partly also by SRT suggests that UMOD excretion
monitoring may be a useful marker, particularly of
response to treatment. We suggest that UMOD might
be an additional marker of therapeutic in situ effect on
Gb3, the excretion of which may be affected by
cleavage of lipid released from the desquamated
storage epithelia by the applied recombinant enzyme
(Christensen et al 2007). Extended study and especial-
ly detailed comparative studies of UMOD expression
in kidney specimens obtained before and during
individual types of available therapies are therefore
of great interest.
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